Sanofi
New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma
Sarclisa SC formulation added to Pd for the treatment of R/R MM met the co-primary endpoints in the IRAKLIA phase 3 study, demonstrating non-inferiority compared to Sarclisa IV IRAKLIA is the first global phase 3 study to evaluate the SC administration of a cancer treatment via an OBDS OBDS is an alternative delivery method designed...
ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients
New analysis from the IMROZ phase 3 study of Sarclisa-VRd demonstrated higher and sustained MRD negativity rates in transplant-ineligible NDMM patients versus VRd alone New detailed results from the GMMG-HD7 phase 3 study of Sarclisa-RVd induction therapy resulted in a significant and clinically meaningful PFS benefit with deeper MRD negativity in transplant-eligible NDMM patients Results...
ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP
Pivotal phase 3 data show rapid and durable platelet response, reduced bleeding and need for rescue response, and improved physical fatigue and quality of life measures in patients with persistent or chronic ITP Results underscore the safety and efficacy of rilzabrutinib and its potential as the first BTK inhibitor in ITP Rilzabrutinib is currently under...
Sanofi wins appeal against negative Final Draft Guidance for its standard-of-care multiple myeloma combination therapy opening the door for a third NICE Committee Meeting
· Sanofi welcomes the decision as recognition from the National Institute for Health and Care Excellence (NICE) that there are challenges with the current framework for assessing and funding innovative combination therapies and there is a need for greater flexibility in certain situations · As part of this extended evaluation process, Sanofi are calling for...
Sanofi launches high-dose egg-based quadrivalent influenza vaccine (QIV-HD) in the UK
Developed with a higher antigen content to increase protection in older adults, a population at greater risk of severe complications from infection. Now available and can be pre-ordered for the first time for the 2025/26 flu season. 15 October 2024 – Reading, UK – Sanofi has today announced the launch of high-dose egg-based quadrivalent influenza...
Sanofi and Orano join forces to develop next-generation radioligand medicines
17 October 2024 -- Paris, France -- Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology, have entered into an agreement to combine their expertise in the fight against rare cancers and further accelerate the development of next-generation radioligand medicines. Building on the...
ERS: Dupixent data reinforce clinically meaningful benefit from pooled analysis of two COPD phase 3 studies
Pooled results from the BOREAS and NOTUS studies show meaningful clinical benefit with 31% reduction in exacerbations along with lung function improvement Data from these two phase 3 studies supported Dupixent as the first-ever biologic approved for certain patients with uncontrolled COPD in the EU. 10 September 2024 -- Paris, France -- A pooled analysis...
Sanofi Consumer Healthcare launches new portal to unlock science and solve key challenges in self-care
Paris, France - June 14, 2023 - Sanofiís Consumer Healthcare Business Unit has today launched a new Open Innovation Portal, allowing the wider supply chain community to submit their creative, disruptive, and game-changing solutions to meet the challenges of an ever-evolving consumer healthcare landscape. Startups, entrepreneurs, research institutions, accelerators, universities and more can now respond...
Sanofi announces launch of AVAXIM Junior in the UK for active immunisation against infection caused by the hepatitis A virus in children aged 12 months to 15 years
Reading, 24 April 2023. Sanofi (EURONEXT: SAN and NASDAQ: SNY) has today announced the launch of AVAXIM Junior in the UK, an inactive hepatitis A vaccine indicated for use in children aged 12 months to 15 years inclusive to prevent infection caused by the hepatitis A virus. The vaccination schedule consists of two vaccine doses...
Acoziborole: Investigational single-dose oral treatment raises hope for elimination of sleeping sickness in Africa
Geneva, Kinshasa, Paris - November 30, 2022. The Drugs for Neglected Diseases initiative (DNDi) and Sanofi announce treatment success rates of up to 95% from a Phase II/III study investigating the safety and efficacy of single-dose acoziborole, a potentially transformative investigational treatment for sleeping sickness, published today in The Lancet Infectious Diseases medical journal. The...
